Latest News and Successes
Pharmaceutical Contract Services
Sales and Marketing
Strategy and Transformation
Chief Executive Officers
Diversity and Inclusion
Biosimilars and their launch price considerations
Introduction "Biosimilar" medicines are characteristically different from generic medicines because of their molecular size and structure, together with the sheer complexity and cost of their development. For example, a 500mg ...
Psychometrics in assessing executives
Companies are increasingly using psychometric tests to assess and ensure they recruit the right executives to bring positive change to their businesses. It brings a scientific element to executive recruitment that utilises data ...
The importance of stress reduction for CEOs
This week is national stress awareness week and we have seen a lot of articles on how to help ease and remove stress for employees within a business but very little on how CEOs can manage their stress and ultimately reduce it. ...
Do consumers need branded generics?
Branded products are certainly good for the brand owner’s bottom line–but are they good for the consumer? Current received wisdom says no. As Naomi Klein argued in No Logo, greater access to information should logically mean ...
The Complex Biosimilar Regulations in Europe
There are a lot of major advancements linked to biological medicines, including many pathological conditions such as autoimmune diseases and cancer. Biosimilars, a lower cost alternative to many biological medicines, have booste ...
API Onshoring in the Pharmaceutical Industry
The COVID-19 pandemic had a huge impact on the pharmaceutical industry; it disrupted supply chains, delayed production and led to a shortage of medicines. In fact, it’s estimated that close to half of acute care medicines - whic ...
Two lessons every industry can learn from pharma
If you think there’s too much red tape in your industry, spare a thought for pharma. Pharma manufacturers are subject to 76,000 restrictions–and with patients’ lives on the line, they need to take every one of them seriously. ...
New Appointment - Brendan O'Grady
Parsity Group successfully appoints Brendan O’Grady as CEO Formulations Business for Glenmark Pharmaceuticals. Parsity Group are pleased to announce their successful partnership with Glenmark Pharmaceuticals to secure Brendan O ...
6 Challenges to Generics and Biosimilars Market
6 Things That Could Challenge the Generics and Biosimilars Market Back in 2020, the worldwide pharmaceutical market had a value of $1.27 trillion; $387.92 billion and $28.235 billion of this was made up of the generics market and ...
© Copyright 2022 Parsity Group